Search Results - "Dy, G. K."

A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study by Dy, G. K., Miller, A. A., Mandrekar, S. J., Aubry, M.-C., Langdon, R. M., Morton, R. F., Schild, S. E., Jett, J. R., Adjei, A. A.

“…Background: The aim of the present study was to evaluate the clinical activity of imatinib mesylate in patients with recurrent and refractory c-kit-expressing…”
Get full text

A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer by Ramnath, N., Daignault-Newton, S., Dy, G. K., Muindi, J. R., Adjei, A., Elingrod, V. L., Kalemkerian, G. P., Cease, K. B., Stella, P. J., Brenner, D. E., Troeschel, S., Johnson, C. S., Trump, D. L.

“…Background Preclinical studies demonstrated antiproliferative synergy of 1,25-D 3 (calcitriol) with cisplatin. The goals of this phase I/II study were to…”
Get full text

Farnesyl transferase inhibitors as anticancer agents by Haluska, P, Dy, G.K, Adjei, A.A

“…Protein farnesylation catalysed by the enzyme farnesyl protein transferase involves the addition of a 15-carbon farnesyl group to conserved amino acid residues…”
Get full text

Novel pharmacological agents in clinical development for solid tumours by Dy, G K, Haluska, P, Adjei, A A

“…For decades, cancer therapy has focused on DNA-directed mechanisms of cytotoxicity, utilising agents with limited efficacy and significant toxicity. Recent…”
Get more information

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer by Drilon, Alexander, Oxnard, Geoffrey R, Tan, Daniel S.W, Loong, Herbert H.F, Johnson, Melissa, Gainor, Justin, McCoach, Caroline E, Gautschi, Oliver, Besse, Benjamin, Cho, Byoung C, Peled, Nir, Weiss, Jared, Kim, Yu-Jung, Ohe, Yuichiro, Nishio, Makoto, Park, Keunchil, Patel, Jyoti, Seto, Takashi, Sakamoto, Tomohiro, Rosen, Ezra, Shah, Manisha H, Barlesi, Fabrice, Cassier, Philippe A, Bazhenova, Lyudmila, De Braud, Filippo, Garralda, Elena, Velcheti, Vamsidhar, Satouchi, Miyako, Ohashi, Kadoaki, Pennell, Nathan A, Reckamp, Karen L, Dy, Grace K, Wolf, Jürgen, Solomon, Benjamin, Falchook, Gerald, Ebata, Kevin, Nguyen, Michele, Nair, Binoj, Zhu, Edward Y, Yang, Luxi, Huang, Xin, Olek, Elizabeth, Rothenberg, S. Michael, Goto, Koichi, Subbiah, Vivek

“…RET fusion–positive lung cancer accounts for 1 to 2% of non–small-cell lung cancers. Among previously treated patients with RET fusion–positive lung cancer,…”
Get full text

A phase 1 study evaluating the pharmacokinetics (PK) and safety of regorafenib (REG) in patients with advanced solid tumors with severe renal impairment (SRI) by Renouf, D.J., Hirte, H.W., O'Bryant, C.L., Trnkova, Z.J., Cleton, A., Huang, F., Mueller, U., Ayoub, J.-P., Lockhart, A.C., Quinn, D.I., Dy, G.K., Sawyer, M.B.

Get full text

First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel by Gupta, Neha, Hatoum, Hassan, Dy, Grace K

“…Lung cancer is the leading cause of cancer mortality worldwide in both men and women. Non-small-cell lung cancer (NSCLC) is the most common type of lung…”
Get full text

A phase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 with paclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), in patients with advanced non-small cell lung cancer (NSCLC) by Besse, B., Soria, J., Gomez-Roca, C., Ware, J. A., Adjei, A. A., Dy, G. K., Shankar, G., Brachmann, R. K., Groen, H. J.

“…Abstract only…”
Get full text

Final results of a phase I study of the combination of a novel cell cycle inhibitor ON 01910.Na with gemcitabine in patients with advanced pancreatic and other solid tumors by Ma, W. W., Messersmith, W. A., Dy, G. K., Freas, E., Whitworth, A., Wilhelm, F., Eckhardt, S. G., Adjei, A. A., Jimeno, A.

“…Abstract only…”
Get full text

Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES SCLC) by Schneider, B. J., Gadgeel, S. M., Ramnath, N., Wozniak, A. J., Dy, G. K., Daignault, S., Kalemkerian, G. P.

“…Abstract only…”
Get full text

Incidence of bleeding and thrombosis among elderly patients (pts) undergoing systemic chemotherapy in advanced non-small cell lung cancer (NSCLC): An analysis of North Central Cancer Treatment Group (NCCTG) trials by Qi, Y., Dy, G. K., Nelson, G. D., Schild, S. E., Mandrekar, S. J., Adjei, A. A.

“…Abstract only…”
Get full text

Safety and activity of IPI-504 (retaspimycin hydrochloride) and docetaxel in pretreated patients (pts) with metastatic non-small cell lung cancer (NSCLC) by Riely, G. J., Gettinger, S. N., Stoller, R. G., Gabrail, N. Y., Dy, G. K., Weiss, G. J., Tunkey, C., Skliris, G., Strychor, S., Dunbar, J., DeLucia, D., Ross, R. W., Gray, J. E.

“…Abstract only…”
Get full text

A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second-line therapy in advanced non-small cell lung cancer (NSCLC) of nonsquamous histology: NCCTG N0626 study by Molina, J. R., Dy, G. K., Foster, N. R., Allen Ziegler, K. L., Adjei, A., Rowland, K. M., Aubry, M., Flynn, P. J., Mandrekar, S. J., Schild, S. E., Adjei, A. A.

“…Abstract only…”
Get full text

First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma by Sosman, J. A., Adjei, A. A., LoRusso, P., Michael, S. A., Dy, G. K., Bowditch, A., Chmielowski, B., Lee, S., Walker, R. M., Faucette, S., Izmailova, E. S., Bozon, V., Ribas, A.

“…Abstract only…”
Get full text

Phase I trial of BMS-690514 in combination with paclitaxel/carboplatin (PC) in patients with advanced or metastatic solid tumors by Chow, L. Q., Laurie, S. A., Belani, C. P., Dy, G. K., Fortin, C., Patricia, D., Gupta, A. K., Kopit, J., Zhang, S.

“…Abstract only…”
Get full text

A phase I dose-escalation trial evaluating ARQ 197 administered in combination with sorafenib in adult patients (pts) with advanced solid tumors by Adjei, A. A., Sosman, J. A., Dy, G. K., Ma, W., Fetterly, G. J., Skupien, D., Means, J. A., Savage, R., Chai, F., Puzanov, I.

“…Abstract only…”
Get full text

Rational combination of a novel cell cycle inhibitor ON01910.Na with gemcitabine in patients with advanced solid tumors by Ma, W., Mani, S., Freas, E., Dy, G. K., Ghalib, M. H., Messersmith, W. A., Bellemarre, S., Wilhelm, F., Adjei, A. A., Jimeno, A.

“…Abstract only…”
Get full text

Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer by Gore, L., Lewis, K., Von Hoff, D. D., Weiss, G. J., Ramanathan, R. K., Adjei, A. A., Dy, G. K., Ma, W. W., Clendeninn, N. J., Leffingwell, D. P., Sheedy, B., Iverson, C., Miner, J. N., Shen, Z., Yeh, L., Dubowy, R. L., Jeffers, M., Rajagopalan, P., Weekes, C. D.

“…Abstract only…”
Get full text

Efficacy in selected tumor types in a phase I study of the c-MET inhibitor ARQ 197 in combination with sorafenib by Adjei, A. A., Sosman, J. A., Martell, R. E., Dy, G. K., Goff, L. W., Ma, W. W., Horn, L., Fetterly, G. J., Michael, S. A., Means, J. A., Chai, F., Lamar, M., Strauss, G. M., Chiang, W., Jarboe, J., Schwartz, B. E., Puzanov, I.

“…Abstract only…”
Get full text

N0321: A phase I study of bortezomib, paclitaxel, carboplatin (CBDCA), and radiotherapy (RT) for locally advanced non-small cell lung cancer (NSCLC) by Schild, S. E., Molina, J. R., Dy, G. K., Rowland, K. M., Sarkaria, J. N., Thomas, S. P., Northfelt, D. W., Kugler, J. W., Foster, N. R., Adjei, A. A.

“…Abstract only…”
Get full text